Neil Dimick Net Worth

The estimated Net Worth of Neil F Dimick is at least $4.65 Million dollars as of 21 March 2022. Mr. Dimick owns over 166 units of Mylan NV stock worth over $1,191,920 and over the last 21 years he sold MYL stock worth over $3,031,936. In addition, he makes $430,006 as Non-Executive Independent Director at Mylan NV.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Dimick MYL stock SEC Form 4 insiders trading

Neil has made over 23 trades of the Mylan NV stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 166 units of MYL stock worth $2,631 on 21 March 2022.

The largest trade he's ever made was exercising 62,084 units of Mylan NV stock on 21 November 2006 worth over $538,889. On average, Neil trades about 1,557 units every 42 days since 2003. As of 21 March 2022 he still owns at least 75,200 units of Mylan NV stock.

You can see the complete history of Mr. Dimick stock trades at the bottom of the page.

Neil Dimick biography

Neil F. Dimick CPA serves as Non-Executive Independent Director of the Company. Mr. Dimick serves on the board of directors of Resources Connection, Inc. (NASDAQ: RECN), chairing its Audit Committee and serving on its Compensation Committee. Mr. Dimick previously served as executive vice president and chief financial officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was senior executive vice president and chief financial officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that, Mr. Dimick served as a partner with Deloitte & Touche LLP (“Deloitte”) for eight years. Mr. Dimick also served on the boards of directors of WebMD Health Corp. from 2005 to September 2017, at which time it was purchased by Internet Brands, a portfolio company of investment funds affiliated with Kohlberg Kravis Roberts & Co., LP; Alliance HealthCare Services, Inc. from 2002 to August 2017, at which time it was purchased by Tahoe Investment Group Co., Ltd.; and Thoratec Corporation from 2003 to October 2015, at which time it was purchased by St. Jude Medical, Inc. As previously disclosed, Mr. Dimick will serve as a director of Viatris upon the closing of the Combination. Mr. Dimick’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding accounting, finance, the healthcare industry, international business, corporate governance, public company management, oversight and strategy, and international business transactions.

What is the salary of Neil Dimick?

As the Non-Executive Independent Director of Mylan NV, the total compensation of Neil Dimick at Mylan NV is $430,006. There are 5 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.

How old is Neil Dimick?

Neil Dimick is 70, he's been the Non-Executive Independent Director of Mylan NV since 2016. There are 1 older and 11 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.

Insiders trading at Mylan NV

Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher, and Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.

What does Mylan NV do?

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Complete history of Mr. Dimick stock trades at Mylan NV, Resources Connection Inc, Global X Funds, and Viatris

Mylan NV executives and stock owners

Mylan NV executives and other stock owners filed with the SEC include:

• Heather Bresch,
  Chief Executive Officer, Executive Director
• Rajiv Malik,
  President, Executive Director
• Robert Coury,
  Executive Chairman of the Board
• Mark Parrish,
  Lead Independent Non-Executive Vice Chairman of the Board
• JoEllen Dillon,
  Non-Executive Independent Director
• Neil Dimick,
  Non-Executive Independent Director
• Melina Higgins,
  Non-Executive Independent Director
• Sjoerd Vollebregt,
  Non-Executive Independent Director
• Robert Cindrich,
  Non-Executive Independent Director
• Harry Korman,
  Non-Executive Independent Director
• Randall Vanderveen,
  Non-Executive Independent Director
• Pauline van der Meer Mohr,
  Non-Executive Independent Director
• Richard Mark,
  Non-Executive Independent Director
• Melissa Trombetta,
  Head of Global Investor Relations
• Joseph C Md Maroon,
  Director
• Rodney L Piatt,
  Director
• Paul Campbell,
  See Remarks
• Laboratories Abbott Product...,
  
• Kenneth Scott Parks,
  Chief Financial Officer
• Wendy Cameron,
  Director
• Douglas J Leech,
  Director
• Daniel Martin Jr Gallagher,
  Chief Legal Officer
• Anthony Mauro,
  Chief Commercial Officer
• John D Sheehan,
  EVP and CFO
• Laboratories Abbott Establi...,
  
• Laboratories Laboratoires F...,